MedTrace Logo

Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients

NCT00745914 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-01-10

No results posted yet for this study

Summary

To test the hypothesis that PPAR-gamma agonist, rosiglitazone, induces carotid plaque regression in diabetic ESRD patients on maintenance PD via its anti-inflammatory property.

Conditions

Interventions

DRUG

Pioglitazone

oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks

DRUG

Placebo comparator

Placebo comparator

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Angela YM Wang, MD, FRCP · Queen Mary Hospital, University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2013-09-30
Completion
2013-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00745914 on ClinicalTrials.gov